ADULT Updated: May 5, 2022

Regimen Reference Order

BMT - zoledronic acid for osteoporosis/osteopenia

ARIA: BMT - [zoledronic acid yearly]

Planned Course: Once yearly up to a maximum of 3 years (duration of therapy to be assessed

annually)

Indication for Use: Osteoporosis/Osteopenia; post-allogeneic stem cell transplantation

CVAD: At Provider's discretion

Proceed with treatment if:

Creatinine clearance equal to or greater than 35 mL/minute

- Corrected calcium equal to or greater than 2.1 mmol/L
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

	Pre-treatn	nent Requirements
Drug	Dose	CCMB Administration Guideline
	No	ot Applicable

Treatment	Regimen – BMT -	zoledronic acid for osteoporosis/osteopenia
Establish primary sol	ution 500 mL of: normal	saline
Drug	Dose	CCMB Administration Guideline
zoledronic acid	5 mg	IV in normal saline 100 mL over 15 minutes

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Prior to each zoledronic acid dose

- serum creatinine, urea, calcium and albumin as per Physician's Orders
- Recent patient weight

Drug	Dose	CCMB Administration Guideline
lcium carbonate	1250 mg* (500 mg elemental calcium)	Orally twice daily at physician's discretion (providing 1000 mg elemental calcium per day)
amin D	1000 International Units*	Orally once daily at physician's discretion



DISCHARGE INSTRUCTIONS

- Patient should drink 8 glasses of water on the day of and day after zoledronic acid
- Patient should advise dentist/hygienist that they are receiving zoledronic acid

ADDITIONAL INFORMATION

- zoledronic acid can cause osteonecrosis of the jaw
- zoledronic acid is dosed at 5 mg once yearly provided that patient's creatinine clearance (CrCl) is at least 35 mL/minute. zoledronic acid as part of this BMT regimen is contraindicated in patients with CrCl less than 35 mL/minute

